ONC
NASDAQBeOne Medicines Ltd.
News25/Ratings6
Price$269.25-1.57 (-0.58%)
01:30 PM07:45 PM
News · 26 weeks50-31%
2025-12-142026-06-07
Mix3490d
- Insider14(41%)
- SEC Filings9(26%)
- Other8(24%)
- Analyst2(6%)
- Earnings1(3%)
Latest news
25 items- INSIDERDirector Yi Qingqing sold $65,596 worth of American Depositary Shares (235 units at $279.13), closing all direct ownership in the company (SEC Form 4) (for withholding tax)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- PRBeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development Company to host investor webcast showcasing momentum across solid tumor pipeline BeOne Medicines Ltd. ("BeOne") (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company's high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. Data from three different
- PRBeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLL Data reinforce BeOne's leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With ext
- INSIDERDirector Riva Alessandro sold $65,617 worth of American Depositary Shares (212 units at $309.51), closing all direct ownership in the company (SEC Form 4) (tax liability)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERDirector Dugan Margaret sold $65,636 worth of American Depositary Shares (212 units at $309.60), closing all direct ownership in the company (SEC Form 4) to cover taxes4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERDirector Sanders Corazon (Corsee) D. sold $65,633 worth of American Depositary Shares (212 units at $309.59), closing all direct ownership in the company (SEC Form 4) to cover taxes4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- PRBeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEA Oral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago. The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab)
- INSIDERDirector Baker Bros. Advisors Lp sold $261,981 worth of Ordinary Shares (10,998 units at $23.82) (SEC Form 4) to satisfy withholding tax4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- PRBeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceBeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, with a fireside chat at 10:00 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com. An archived webcast will be available on the Company's website. About BeOne BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipelin
- INSIDERAmendment: New insider Sharp Shalini claimed ownership of 9 units of American Depositary Shares (SEC Form 3)3/A - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERSVP, General Counsel Lee Chan Henry exercised 332 units of American Depositary Shares at a strike of $191.56 and sold $103,159 worth of American Depositary Shares (332 units at $310.72) as part of a pre-agreed trading plan (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- SECBeOne Medicines Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BeOne Medicines Ltd. (0001651308) (Filer)
- PRBeOne Medicines' BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell LymphomaBEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the class Approval of BEQALZI marks the first new BCL2 inhibitor approved in a decade in the U.S. and the only BCL2 inhibitor approved in MCL, aiming to set a new standard of innovation BeOne Medicines Ltd. ("BeOne") (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™ (bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or
- SECSEC Form S-3ASR filed by BeOne Medicines Ltd.S-3ASR - BeOne Medicines Ltd. (0001651308) (Filer)
- SECSEC Form S-3ASR filed by BeOne Medicines Ltd.S-3ASR - BeOne Medicines Ltd. (0001651308) (Filer)
- SECSEC Form 10-Q filed by BeOne Medicines Ltd.10-Q - BeOne Medicines Ltd. (0001651308) (Filer)
- SECBeOne Medicines Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BeOne Medicines Ltd. (0001651308) (Filer)
- PRBeOne Medicines Announces First Quarter 2026 Financial Results and Business UpdatesTotal global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year Foundational BRUKINSA (zanubrutinib) global revenues of $1.1 billion for the first quarter, an increase of 38% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of $1.96 for the first quarter; non-GAAP diluted Earnings per ADS of $3.24 for the first quarter BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the first quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: "These strong first-quarter results reinforce BeOne's conti
- PRU.S. FDA Grants Priority Review to BeOne Medicines' TEVIMBRA in First-Line HER2+ GEATEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging disease Results from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally ad
- SECSEC Form DEF 14A filed by BeOne Medicines Ltd.DEF 14A - BeOne Medicines Ltd. (0001651308) (Filer)
- SECSEC Form DEFA14A filed by BeOne Medicines Ltd.DEFA14A - BeOne Medicines Ltd. (0001651308) (Filer)
- PRBeOne Medicines to Announce First Quarter 2026 Financial Results on May 6BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company's website. About BeOne Medicines BeOne Medicines is a global oncol
- SECAmendment: SEC Form SCHEDULE 13D/A filed by BeOne Medicines Ltd.SCHEDULE 13D/A - BeOne Medicines Ltd. (0001651308) (Subject)
- SECSEC Form PRE 14A filed by BeOne Medicines Ltd.PRE 14A - BeOne Medicines Ltd. (0001651308) (Filer)
- SECBeOne Medicines Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - BeOne Medicines Ltd. (0001651308) (Filer)
ONC FAQ
6 questionsWhere does ONC stock trade?
BeOne Medicines Ltd. (ONC) is listed on NASDAQ.What sector and industry is ONC in?
BeOne Medicines Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did BeOne Medicines Ltd. go public?
BeOne Medicines Ltd. (ONC) completed its IPO in 2016.What are analysts saying about ONC?
BeOne Medicines Ltd. has had 6 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-03-27.What companies are similar to ONC?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ONC side-by-side with any of them on Quantisnow.How can I track ONC on Quantisnow?
Quantisnow aggregates BeOne Medicines Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ONC to receive live email and push alerts on every new disclosure.